- Home
- IDN vs ACTU Comparison
IDN vs ACTU Comparison
Compare IDN & ACTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDN
- ACTU
- Stock Information
- Founded
- IDN 1994
- ACTU 2015
- Country
- IDN United States
- ACTU United States
- Employees
- IDN N/A
- ACTU N/A
- Industry
- IDN Computer Software: Prepackaged Software
- ACTU
- Sector
- IDN Technology
- ACTU
- Exchange
- IDN Nasdaq
- ACTU NYSE
- Market Cap
- IDN 120.5M
- ACTU 135.0M
- IPO Year
- IDN 1999
- ACTU 2024
- Fundamental
- Price
- IDN $5.35
- ACTU $6.39
- Analyst Decision
- IDN Strong Buy
- ACTU Strong Buy
- Analyst Count
- IDN 3
- ACTU 1
- Target Price
- IDN $5.83
- ACTU $20.00
- AVG Volume (30 Days)
- IDN 481.3K
- ACTU 133.1K
- Earning Date
- IDN 08-07-2025
- ACTU 05-15-2025
- Dividend Yield
- IDN N/A
- ACTU N/A
- EPS Growth
- IDN N/A
- ACTU N/A
- EPS
- IDN N/A
- ACTU N/A
- Revenue
- IDN $20,211,000.00
- ACTU N/A
- Revenue This Year
- IDN $9.35
- ACTU N/A
- Revenue Next Year
- IDN $13.05
- ACTU N/A
- P/E Ratio
- IDN N/A
- ACTU N/A
- Revenue Growth
- IDN 4.55
- ACTU N/A
- 52 Week Low
- IDN $1.92
- ACTU $5.50
- 52 Week High
- IDN $6.49
- ACTU $11.99
- Technical
- Relative Strength Index (RSI)
- IDN 59.07
- ACTU N/A
- Support Level
- IDN $5.21
- ACTU N/A
- Resistance Level
- IDN $5.97
- ACTU N/A
- Average True Range (ATR)
- IDN 0.39
- ACTU 0.00
- MACD
- IDN -0.10
- ACTU 0.00
- Stochastic Oscillator
- IDN 29.01
- ACTU 0.00
About IDN Intellicheck Inc.
Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The group delivers on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. The products of the company include solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.